For research and educational purposes only. Not medical advice.
GHRP-2 Reference
Educational, not medical advice reference for GHRP-2: GH Release; regulatory status, evidence posture, source review, and schedule notes. Also known as Pralm…
Reference summary
Clinical data exist primarily as GH-release provocative testing in adult and pediatric populations, supporting its Japanese diagnostic approval. Long-term therapeutic outcome data are limited.
- Categories
- GH Release
- Aliases
- Pralmorelin, KP-102, GHRP2
- Evidence posture
- human — Approved only as a diagnostic in Japan; no US therapeutic approval. Long-term outcome data are limited.
- Regulatory status
- GHRP-2 (pralmorelin) is approved in Japan only as a diagnostic agent for GH deficiency. There is no FDA-approved GHRP-2 drug label in the US. FDA lists GHRP-2 among bulk drug substances with safety-risk concerns for compounding.
- Content review status
- research reference